Shares of Siegfried fell sharply after an influential broker revised its outlook on the Swiss contract drug manufacturer. UBS moved the stock from Buy to Neutral and cut its price target by one-third, taking it down from CHF 120 to CHF 80. The rating change coincided with a nearly 3.9% decline in Siegfried's share price to CHF 69.6, with the stock touching an intraday 52-week low of CHF 67.25 before recovering modestly.
UBS's reassessment rests on a reassessment of Siegfried's short-term growth prospects. The bank highlighted slower-than-expected timelines for newly built manufacturing capacities coming online. In addition, UBS said the revenue contribution from a U.S. business acquired in recent quarters has been weaker than anticipated, reducing the near-term upside in top-line momentum.
As part of the revision, UBS lowered its earnings-per-share projections for fiscal years 2026 through 2028 by roughly 7%. Those downward EPS adjustments reflect the bank's view that a previously projected acceleration in growth is unlikely to occur on the earlier timetable. UBS also expects Siegfried's 2026 organic sales growth to be concentrated in the second half of the year, a pattern that the bank said undermines near-term earnings visibility and makes the investment case harder to defend at prior valuation levels.
The selloff in Siegfried stood out as largely company-specific. U.S. equity benchmarks were trading firmly higher during the session, with technology stocks leading gains, a backdrop that would normally support risk assets rather than weigh on them. Meanwhile, Switzerland's benchmark index has been consolidating in a roughly 13,000 to 13,500 range in recent weeks, providing no clear negative market-wide catalyst to explain the decline.
Taken together, UBS's combination of a downgrade, a steep price-target reduction and downward earnings revisions was the dominant driver behind the move lower in Siegfried's shares. Those factors outweighed broader positive market momentum and pushed the stock to its lowest level in the past year.